Anti-CDH3/MMAE Antibody-drug Conjugate BC3195

**Semantic type:** Amino Acid, Peptide, or Protein|Pharmacologic Substance

**Definition:** An antibody-drug conjugate (ADC) composed of a monoclonal antibody directed against the human tumor-associated antigen (TAA) cadherin-3 (CDH3; placental cadherin; P-cadherin), conjugated to the auristatin derivative and microtubule-disrupting cytotoxic agent monomethyl auristatin E (MMAE) via a valine-citrulline (VC) peptide linker, with potential antineoplastic activity. Upon administration of anti-CDH3/MMAE ADC BC3195, the monoclonal antibody moiety targets and binds to CDH3 expressed on tumor cells. Upon internalization, proteolytic cleavage of linker, and the release of MMAE, MMAE targets and binds to tubulin, and inhibits microtubule polymerization. This results in G2/M phase cell cycle arrest and apoptosis in CDH3-expressing tumor cells. In addition, BC3195 is able to induce a bystander effect on neighboring tumor cells. CDH3 is a member of the cadherin family; it is overexpressed in a variety of tumors and plays a role in cell adhesion, motility, invasion, and proliferation.

**Synonyms:** - Anti-CDH3 ADC BC3195 - Anti-CDH3 Antibody-drug Conjugate BC3195 - Anti-CDH3/MMAE ADC BC3195 - BC 3195 - BC-3195 - BC3195